Clinical Scorecard: Successful Treatment of Primary Plasma Cell Leukemia with Sequential Allogeneic Hematopoietic Stem Cell Transplantation Following Combination Chemotherapy: A Case Study
At a Glance
Category
Detail
Condition
Key Mechanisms
Combination chemotherapy followed by allogeneic peripheral blood hematopoietic stem cell transplantation (allo-PBSCT) as per IMWG guidelines.
Target Population
Care Setting
Key Highlights
pPCL is characterized by acute onset, short disease course, and poor prognosis.
The IMWG updated diagnostic criteria for pPCL to include ≥5% circulating plasma cells.
The patient achieved complete remission after three courses of DCEP+T chemotherapy.
Complete donor chimerism was observed one month post-transplant.
Guideline-Based Recommendations
Diagnosis
Diagnosis of pPCL requires ≥5% circulating plasma cells according to IMWG criteria.
Management
Intense chemotherapy followed by hematopoietic stem cell transplantation is recommended by IMWG.
Monitoring & Follow-up
Monitor for complete donor chimerism and disease remission post-transplant.
Risks
Potential risks include graft-versus-host disease and complications from chemotherapy.
Patient & Prescribing Data
A 47-year-old female with pPCL and extramedullary infiltration.
Patient received DCEP+T chemotherapy followed by allo-HSCT with a 7/10 HLA matched donor.
Clinical Best Practices
Consider bortezomib-based regimens for chemotherapy in pPCL.
Ensure thorough monitoring of chimerism and plasma cell levels post-transplant.
